PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma : a real-world data
© 2024. The Author(s)..
BACKGROUND: Chemotherapy combined with immune checkpoint inhibitors (IC), bevacizumab (BC), or both (IBC) is the preferred first-line therapy for PD-L1-negative and oncogenic-driver wild-type metastatic lung adenocarcinoma. However, the optimal strategy is still undetermined.
METHODS: This retrospective study enrolled PD-L1-negative metastatic lung adenocarcinoma patients from four cancer centers between January 1, 2018 and June 30, 2022. All the patients received IC, BC, or IBC as the first-line therapies. The efficacy and safety were evaluated.
RESULTS: A total of 205 patients were included, with 60, 83, and 62 patients in IC, BC, and IBC groups, respectively. The baseline characteristics among three groups were well balanced. Patients treated with IBC had the highest objective response rate (ORR) (43.5%) and disease control rate (DCR) (100%) relative to those treated with IC (40.4%, 84.2%) or BC (40.5%, 96.2%) (ORR: P = 0.919, DCR: P < 0.01). Compared with the IC (6.74 m) or BC (8.28 m), IBC treatment significantly improved median progression-free survival (mPFS) (9.53 m, P = 0.005). However, no difference in overall survival (OS) was observed. When stratified by different clinical and molecular information, we found that male gender, ever smoking, wild-type genes mutations, and adrenal metastasis predict superior PFS benefit when treated with IBC. In patients with liver metastasis, IBC or BC treatment displayed better PFS compared with IC. No additional adverse reactions were observed in IBC group compared with other two groups.
CONCLUSION: Combined IBC treatment achieved superior DCR and PFS compared with IC or BC in patients with PD-L1-negative metastatic lung adenocarcinoma, while did not increase the adverse events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:150 |
|---|---|
| Enthalten in: |
Journal of cancer research and clinical oncology - 150(2024), 3 vom: 18. März, Seite 135 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ge, Yihui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2S9ZZM9Q9V |
|---|
| Anmerkungen: |
Date Completed 20.03.2024 Date Revised 13.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00432-024-05637-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369894839 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369894839 | ||
| 003 | DE-627 | ||
| 005 | 20240413232559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00432-024-05637-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1374.xml |
| 035 | |a (DE-627)NLM369894839 | ||
| 035 | |a (NLM)38499838 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ge, Yihui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma |b a real-world data |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2024 | ||
| 500 | |a Date Revised 13.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Chemotherapy combined with immune checkpoint inhibitors (IC), bevacizumab (BC), or both (IBC) is the preferred first-line therapy for PD-L1-negative and oncogenic-driver wild-type metastatic lung adenocarcinoma. However, the optimal strategy is still undetermined | ||
| 520 | |a METHODS: This retrospective study enrolled PD-L1-negative metastatic lung adenocarcinoma patients from four cancer centers between January 1, 2018 and June 30, 2022. All the patients received IC, BC, or IBC as the first-line therapies. The efficacy and safety were evaluated | ||
| 520 | |a RESULTS: A total of 205 patients were included, with 60, 83, and 62 patients in IC, BC, and IBC groups, respectively. The baseline characteristics among three groups were well balanced. Patients treated with IBC had the highest objective response rate (ORR) (43.5%) and disease control rate (DCR) (100%) relative to those treated with IC (40.4%, 84.2%) or BC (40.5%, 96.2%) (ORR: P = 0.919, DCR: P < 0.01). Compared with the IC (6.74 m) or BC (8.28 m), IBC treatment significantly improved median progression-free survival (mPFS) (9.53 m, P = 0.005). However, no difference in overall survival (OS) was observed. When stratified by different clinical and molecular information, we found that male gender, ever smoking, wild-type genes mutations, and adrenal metastasis predict superior PFS benefit when treated with IBC. In patients with liver metastasis, IBC or BC treatment displayed better PFS compared with IC. No additional adverse reactions were observed in IBC group compared with other two groups | ||
| 520 | |a CONCLUSION: Combined IBC treatment achieved superior DCR and PFS compared with IC or BC in patients with PD-L1-negative metastatic lung adenocarcinoma, while did not increase the adverse events | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a First-line therapy | |
| 650 | 4 | |a Lung adenocarcinoma | |
| 650 | 4 | |a PD-L1 negative | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 700 | 1 | |a Zhan, Yujing |e verfasserin |4 aut | |
| 700 | 1 | |a He, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Xiaojuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chunni |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Aiqin |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yuping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and clinical oncology |d 1981 |g 150(2024), 3 vom: 18. März, Seite 135 |w (DE-627)NLM000394610 |x 1432-1335 |7 nnns |
| 773 | 1 | 8 | |g volume:150 |g year:2024 |g number:3 |g day:18 |g month:03 |g pages:135 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00432-024-05637-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2024 |e 3 |b 18 |c 03 |h 135 | ||